RB1 gene mutations underlie clinical resistance to CDK 4/6 inhibitor breast cancer therapy

KeepHealthCare.ORG – RB1 gene mutations underlie clinical resistance to CDK 4/6 inhibitor breast cancer therapy A multi-institutional research team has identified what may be a novel mechanism underlying acquired resistance Continue reading